RESUMEN
OBJECTIVE: To assess the cost-effectiveness of treatment with nifedipine compared with atosiban in women with threatened preterm birth. DESIGN: An economic analysis alongside a randomised clinical trial (the APOSTEL III study). SETTING: Obstetric departments of 12 tertiary hospitals and seven secondary hospitals in the Netherlands and Belgium. POPULATION: Women with threatened preterm birth between 25 and 34 weeks of gestation, randomised for tocolysis with either nifedipine or atosiban. METHODS: We performed an economic analysis from a societal perspective. We estimated costs from randomisation until discharge. Analyses for singleton and multiple pregnancies were performed separately. The robustness of our findings was evaluated in sensitivity analyses. MAIN OUTCOME MEASURES: Mean costs and differences were calculated per woman treated with nifedipine or atosiban. Health outcomes were expressed as the prevalence of a composite of adverse perinatal outcomes. RESULTS: Mean costs per patients were significantly lower in the nifedipine group [singleton pregnancies: 34,897 versus 43,376, mean difference (MD) -8479 [95% confidence interval (CI) -14,327 to -2016)]; multiple pregnancies: 90,248 versus 102,292, MD -12,044 (95% CI -21,607 to -1671). There was a non-significantly higher death rate in the nifedipine group. The difference in costs was mainly driven by a lower neonatal intensive care unit admission (NICU) rate in the nifedipine group. CONCLUSION: Treatment with nifedipine in women with threatened preterm birth results in lower costs when compared with treatment with atosiban. However, the safety of nifedipine warrants further investigation. TWEETABLE ABSTRACT: In women with threatened preterm birth, tocolysis using nifedipine results in lower costs when compared with atosiban.
Asunto(s)
Nifedipino/economía , Nacimiento Prematuro/economía , Tocolíticos/economía , Vasotocina/análogos & derivados , Análisis Costo-Beneficio , Femenino , Humanos , Nifedipino/uso terapéutico , Embarazo , Embarazo Múltiple , Nacimiento Prematuro/prevención & control , Atención Prenatal/economía , Tocolíticos/uso terapéutico , Vasotocina/economía , Vasotocina/uso terapéuticoRESUMEN
Severe pre-eclampsia and eclampsia are common causes of maternal deaths worldwide and more so in developing countries. Magnesium sulphate (MgSO4) is now the most-recommended drug of choice to treat these conditions. Despite favourable policies for the use of MgSO4 treatment in India, eclampsia continues to take a high toll. This study examined the availability and use of MgSO4 treatment in the public health system and poor women's recent experiences with eclampsia treatment in Maharashtra state. A mix of qualitative and quantative methods was used. A facility-based survey of all secondary and tertiary healthcare facilities (n = 44) in 3 selected districts and interviews with public and contracted-in private sector obstetricians, health officials, and programme managers were conducted. A list of recently-delivering women from marginalized communities, with up to two livebirths, was drawn through a community-level survey in 272 villages covered by 60 subcentres selected at random. Mothers were selected for interviews, using maximum variation sampling, and interviews were conducted with 17% of the mothers who reported having experienced eclampsia; 61% of facilities had no stock of MgSO4, the stock-out position continuing from a period ranging from 3 months to 3 years while another 20% had some stock, although less than the expected minimum quantity. No treatment for eclampsia was provided in the recent 3 months at 73% facilities. Our survey of recently-delivering mothers recorded a history of eclampsia in 3.2% pregnancies/ deliveries. Interviews with 10 such mothers revealed that treatment for eclampsia has been sought from public as well as private hospitals and from traditional healers. However, facilities where women have received medical treatment are exclusively in the private sector. Almost all public and private care providers were aware of MgSO4 as the gold standard to treat eclampsia; however, it is unclear if they knew of its use to treat severe pre-eclampsia. The private care providers routinely used MgSO4 for eclampsia treatment while the public care providers seemed hesitant to use it fearing risks of complications. We stress the need for improved inventory control practices to ensure sustained availability of supplies and building confidence of care providers in using MgSO4 treatment for severe pre-eclampsia and eclampsia in public facilities, in addition to teaching expectant mothers how to recognize symptoms of these conditions.
Asunto(s)
Eclampsia/tratamiento farmacológico , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Disparidades en Atención de Salud/estadística & datos numéricos , Sulfato de Magnesio/uso terapéutico , Tocolíticos/uso terapéutico , Adulto , Países en Desarrollo/estadística & datos numéricos , Eclampsia/economía , Eclampsia/epidemiología , Femenino , Instituciones de Salud/estadística & datos numéricos , Hospitales/estadística & datos numéricos , Hospitales Privados/estadística & datos numéricos , Humanos , Incidencia , India/epidemiología , Sulfato de Magnesio/economía , Embarazo , Tocolíticos/economía , Adulto JovenRESUMEN
INTRODUCTION: Preterm delivery is a significant cause of neonatal morbidity and mortality. Pregnant women, with symptoms and signs consistent with preterm labor, can be treated with various tocolytic drugs. Atosiban is one of many drugs indicated to arrest imminent preterm labor. Various studies show that the efficacy of atosiban is similar to other tocolytic drugs. The main advantage of atosiban is a relativeLy low incidence of adverse maternal reactions. Its considerable shortcoming is the financial cost, compared to other available drugs. AIM: In view of its cost, we have decided to implement a strict protocol to direct the use of atosiban, with the intent to reduce costs, without hampering quality of care. STUDY METHODS: The protocol was implemented from July 2009, and it outlines the medical and procedural terms to use atosiban. We compared similar time periods before and after implementation of the protocol. The outcomes compared included: treatment success, rates of preterm deliveries and financial costs. RESULTS: Within the timeframe that the protocol was implemented, we have been able to demonstrate a 40% reduction in atosiban related costs, compared to a parallel period, when the clinical guidelines were not implemented. This translates into savings of about NIS 40,000 (New Israeli Shekel) (approximately $10,000). This was achieved without an increase in the rate of preterm deliveries. CONCLUSION: Implementing and enforcing a simple protocol of supervision on the use of atosiban enables a considerable reduction of financial costs related to atosiban, without hampering medical care.
Asunto(s)
Trabajo de Parto Prematuro/tratamiento farmacológico , Guías de Práctica Clínica como Asunto , Tocolíticos/uso terapéutico , Vasotocina/análogos & derivados , Ahorro de Costo , Femenino , Humanos , Israel , Embarazo , Nacimiento Prematuro/prevención & control , Calidad de la Atención de Salud , Tocolíticos/efectos adversos , Tocolíticos/economía , Resultado del Tratamiento , Vasotocina/efectos adversos , Vasotocina/economía , Vasotocina/uso terapéuticoRESUMEN
The aim of this study was to determine the cost effectiveness of atosiban compared to betamimetics in the treatment of preterm labour within the Italian setting. A systematic literature review identified randomised controlled trials (RCTs) comparing atosiban with betamimetics. Meta-analysis of nine RCTs determined that atosiban and betamimetics had similar efficacy in delaying preterm birth by at least 48 h (p=0.910). Use of atosiban was associated with significantly fewer adverse events (p<0.008). Results demonstrate that atosiban is cost-saving versus ritodrine or isoxuprine. Atosiban cost savings are 657 per patient from the National Health Service payer's perspective; 299 at 18 h of tocolysis to 189 at 48 h from the hospital's perspective. The respective values versus isoxuprine were 303 and 199. From the combined perspective, using atosiban versus ritodrine saved from 425 to 316; and versus isoxuprine from 429 to 326. Owing to its superior safety profile, atosiban is cost-saving versus betamimetics in the treatment of preterm labour in Italy from the payer's, hospital's and combined perspectives. With the approximate 40,000 annual preterm births in Italy the annual savings could be in excess of 13 million for the payer or 3.8-6.2 million for the hospitals.
Asunto(s)
Agonistas Adrenérgicos beta/uso terapéutico , Trabajo de Parto Prematuro/prevención & control , Vasotocina/análogos & derivados , Agonistas Adrenérgicos beta/efectos adversos , Agonistas Adrenérgicos beta/economía , Análisis Costo-Beneficio , Femenino , Humanos , Isoxsuprina/efectos adversos , Isoxsuprina/economía , Isoxsuprina/uso terapéutico , Italia , Trabajo de Parto Prematuro/economía , Embarazo , Ritodrina/efectos adversos , Ritodrina/economía , Ritodrina/uso terapéutico , Tocolíticos/efectos adversos , Tocolíticos/economía , Tocolíticos/uso terapéutico , Vasotocina/efectos adversos , Vasotocina/economía , Vasotocina/uso terapéuticoRESUMEN
PURPOSE: Beta-2 adrenoceptor agonistic drugs like ritodrine have been the reference tocolytic drugs, but are associated with cardiovascular side-effects. Atosiban, a newer drug, is a competitive antagonist of oxytocin and has been claimed to have fewer cardiovascular side effects. Until now, there has mainly been a subjective reporting of adverse reactions and few objective cardiovascular data. Evaluation of the acute effects of therapeutic doses of ritodrine and atosiban compared with placebo on cardiac function, large artery properties, blood pressure, and resistance vessels. METHODS: A double-blind, randomized trial was carried out in 20 non-pregnant female volunteers. Hemodynamic measurements were made under standardized conditions during kinetic steady state. Cardiac output was measured with echocardiography, large artery properties with an echo-tracking device. The effect on the microcirculation was estimated using the total peripheral resistance index (TPRI). RESULTS: Atosiban did not differ from placebo. With ritodrine, cardiac function increased by 79% compared with placebo because of a rise in heart rate (91%). TPRI decreased by 48%. Ritodrine increased the distensibility of the common carotid artery by 62% and the compliance by 83%, independent of blood pressure. Compliance of the common femoral artery increased independently of pressure by 33% and the distensibility by 59%. Aortic pulse wave velocity was not influenced by either medication. CONCLUSIONS: The present study shows potential beneficial vascular effects of ritodrine that are counterbalanced by the cardiac effects. Atosiban has no clinically relevant cardiovascular effects and may be a good alternative for ritodrine in pregnant women at risk of cardiovascular complications.
Asunto(s)
Arterias/efectos de los fármacos , Fenómenos Fisiológicos Cardiovasculares/efectos de los fármacos , Ritodrina/uso terapéutico , Tocolíticos/uso terapéutico , Resistencia Vascular/efectos de los fármacos , Vasotocina/análogos & derivados , Adolescente , Adulto , Presión Sanguínea/efectos de los fármacos , Gasto Cardíaco/efectos de los fármacos , Método Doble Ciego , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Oxitocina/antagonistas & inhibidores , Placebos , Ritodrina/efectos adversos , Ritodrina/economía , Tocolíticos/efectos adversos , Tocolíticos/economía , Vasotocina/efectos adversos , Vasotocina/economía , Vasotocina/uso terapéutico , Adulto JovenRESUMEN
OBJECTIVE: The objective of this study was to determine the cost-effectiveness of using transdermal nitroglycerin (GTN) for cases of preterm labor. METHODS: The study included 153 women with clinical preterm labor, who were randomly allocated to either a GTN or placebo arm. All randomized cases were included in the final economic analysis. Differences between the two arms in gestational age at delivery, neonatal intensive care unit (NICU) admission, length of NICU stay, and NICU cost were assessed. Costs for non-NICU cases were calculated using Ottawa Hospital data through the Ontario Case Costing Initiative (OCCI). Cost-effectiveness and sensitivity analyses using a hospital perspective were both conducted. RESULTS: In the 153 randomized cases, 55 babies were admitted to NICU (GTN = 24; placebo = 31). We found no significant differences between the two arms in gestational age at delivery, NICU admission rate (32.4% vs. 39.2%), NICU length of stay (42.7 days vs. 52.8 days), or NICU cost (CAN $34,306 vs. CAN $44,326). Overall, (based on all randomized cases) the cost-effectiveness analyses showed that the GTN arm was the dominant strategy, with both lower cost (CAN $13,397 vs. CAN $18,427) and higher NICU admission avoided rate (67.6% vs. 60.8%) compared to the placebo arm. This dominance persisted in all sensitivity analyses. CONCLUSION: The use of GTN patch for preterm labor could reduce NICU costs, while improving important neonatal outcomes.
Asunto(s)
Unidades de Cuidado Intensivo Neonatal/economía , Nitroglicerina/administración & dosificación , Nitroglicerina/economía , Trabajo de Parto Prematuro/economía , Trabajo de Parto Prematuro/prevención & control , Resultado del Embarazo/economía , Administración Cutánea , Canadá , Femenino , Edad Gestacional , Humanos , Recién Nacido , Tiempo de Internación , Trabajo de Parto Prematuro/tratamiento farmacológico , Embarazo , Tocolíticos/administración & dosificación , Tocolíticos/economíaRESUMEN
We examined pregnancy outcomes in women receiving nifedipine tocolysis having recurrent preterm labor (RPTL). Singleton gestations enrolled for outpatient nursing surveillance and prescribed nifedipine tocolysis were identified (N = 4748). Women hospitalized for RPTL at <35 weeks then resuming outpatient surveillance were included (N = 1366). Pregnancy outcomes of women resuming nifedipine (N = 830) were compared with those having an alteration in treatment to continuous subcutaneous terbutaline (N = 536). Overall, 56.7% (2692/4748) experienced RPTL. Half (50.7%) were stabilized and resumed outpatient surveillance with nifedipine or continuous subcutaneous terbutaline. Infants from women resuming nifedipine versus those with alteration of treatment to terbutaline were more likely to deliver at <35 weeks (28.0% versus 13.8%), weigh <2500 g (32.9% versus 20.3%), and require a stay in the neonatal intensive care unit (34.0% versus 23.1%), all P < 0.001. Alteration of tocolytic treatment following RPTL resulted in a decreased incidence of preterm birth and low birth weight, resulting in less admission to the neonatal intensive care unit and fewer nursery days.
Asunto(s)
Nifedipino/economía , Trabajo de Parto Prematuro/prevención & control , Resultado del Embarazo , Terbutalina/economía , Tocolíticos/economía , Adulto , Análisis Costo-Beneficio , Femenino , Humanos , Nifedipino/administración & dosificación , Trabajo de Parto Prematuro/tratamiento farmacológico , Embarazo , Recurrencia , Terbutalina/administración & dosificación , Tocolíticos/uso terapéuticoRESUMEN
BACKGROUND: The use of tocolytic hospitalization in antenatal care is controversial and worthy of more research. We investigated individual, institutional, and area factors that affect the use of tocolytic hospitalizations in Taiwan where fertility has rapidly declined. METHODS: Longitudinal data from the 1996 to 2004 National Health Insurance Research Database in Taiwan were used to identify tocolytic hospitalizations. The probit model was used to estimate factors associated with tocolytic hospitalizations. RESULTS: The decline in fertility was significantly associated with the probability of tocolytic hospitalizations. Several physician and institutional factors-including physician's age, hospital ownership, accreditation status, bed size, and teaching status-were also significantly correlated to the dependent variables. CONCLUSIONS: The provision of inpatient tocolysis is influenced not only by clinical considerations but also by physician, institutional, and area factors unrelated to clinical need. Fertility declines in Taiwan may have led obstetricians/gynecologists to provide more tocolysis to make up for their lost income. If the explanation is further validated, reimbursement policies may need to be reviewed to correct for overuse of inpatient tocolysis. The correlation could also be explained by the increasing use of artificial reproductive technologies and higher social value of newborns. In addition, the physician and institutional variations observed in the study indicate potential misuse of inpatient tocolysis that warrant further investigation.
Asunto(s)
Tiempo de Internación/estadística & datos numéricos , Registros Médicos/estadística & datos numéricos , Trabajo de Parto Prematuro/epidemiología , Trabajo de Parto Prematuro/prevención & control , Tocólisis/estadística & datos numéricos , Tocolíticos/administración & dosificación , Adulto , Estudios Transversales , Femenino , Mal Uso de los Servicios de Salud/estadística & datos numéricos , Investigación sobre Servicios de Salud , Hospitalización/estadística & datos numéricos , Humanos , Estudios Longitudinales , Trabajo de Parto Prematuro/economía , Admisión del Paciente/estadística & datos numéricos , Embarazo , Atención Prenatal/estadística & datos numéricos , Factores Socioeconómicos , Taiwán/epidemiología , Tocólisis/economía , Tocólisis/métodos , Tocolíticos/economía , Adulto JovenRESUMEN
Our objective was to assess the effectiveness, safety and efficiency of a protocol combining fetal fibronectin diagnostic testing and atosiban tocolysis for the management of pre-term labour, using a combination of narrative review and economic modelling. We compared the proposed protocol to alternatives using nifedipine with or without fetal fibronectin. We have found that the proposed protocol may be safer and more acceptable by women than the alternatives, and its use can result in significant cost-savings.
Asunto(s)
Fibronectinas/análisis , Trabajo de Parto Prematuro/tratamiento farmacológico , Tocolíticos/uso terapéutico , Vasotocina/análogos & derivados , Árboles de Decisión , Femenino , Investigación sobre Servicios de Salud , Humanos , Nifedipino/uso terapéutico , Trabajo de Parto Prematuro/economía , Embarazo , Tocolíticos/economía , Vasotocina/economía , Vasotocina/uso terapéuticoRESUMEN
BACKGROUND: The use of tocolytics is central in delaying birth; however, therapeutic options vary in effectiveness and adverse events profiles, which in turn could have consequences for medical resource use and cost of treatment. Betamimetics are commonly used tocolytic agents, but their mechanism of action affects multiple organ systems leading to numerous adverse events. The availability of an oxytocin receptor antagonist, specific for prevention of preterm labour, offers a treatment option that merits further evaluation. We aimed to compare economic implications of tocolysis using atosiban and betamimetics, considering treatment efficacy and safety, as well as cost consequences of treatment of associated adverse events. METHODS: A systematic literature review identified six randomised clinical trials, three of them double-blinded, comparing atosiban with betamimetics, in which tocolysis was initiated within 48 hours of admission. Cost of drug treatment was calculated based on trial protocols and German hospital drug purchase costs. G-DRG Grouper was used to obtain cost per case. The drug regimen was concordant with the German guidelines for the management of preterm labour, with two alternative modalities of fenoterol analysed: continuous or bolus administrations. RESULTS: According to the results of the meta-analysis of the three double-blinded, placebo-controlled clinical trials, atosiban and betamimetics have similar efficacy (RR = 0.99, 95%CI:0.94-1.04, p = 0.772). Compared to betamimetics, use of atosiban was associated with a significantly lower frequency of adverse events for tachycardia, palpitation, vomiting, headache, hyperglycaemia, tremor, dyspnoea, chest pain, hypocalemia and foetal tachycardia. In our economic analysis, cost savings from using atosiban versus continuous, or bolus, fenoterol was 423euro per patient from the payer's perspective. From the hospital's perspective, savings from using atosiban versus continuous fenoterol ranged from 259euro for 18 hours of tocolysis to 105euro for 48 hours; the respective values for bolus fenoterol were 244euro and 55euro. In the probabilistic sensitivity analysis atosiban was cost saving versus both continuous and bolus fenoterol in 87%-100% of scenarios. CONCLUSION: In a German setting, atosiban is cost saving versus betamimetics in the treatment of preterm labour from the payer, hospital and combined perspectives. Cost savings stem from the superior safety profile of atosiban.
Asunto(s)
Agonistas Adrenérgicos beta/economía , Costos de los Medicamentos , Trabajo de Parto Prematuro/tratamiento farmacológico , Tocolíticos/economía , Vasotocina/análogos & derivados , Agonistas Adrenérgicos beta/efectos adversos , Agonistas Adrenérgicos beta/uso terapéutico , Análisis Costo-Beneficio , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Femenino , Alemania , Humanos , Modelos Econométricos , Embarazo , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Tocolíticos/efectos adversos , Tocolíticos/uso terapéutico , Vasotocina/efectos adversos , Vasotocina/economía , Vasotocina/uso terapéuticoRESUMEN
OBJECTIVES: In countries with high income, tocolytic therapy with beta-mimetic agents is a cost-effective strategy compared to placebo. In our study, the cost-effectiveness of two beta-mimetic agents, ritodrine and fenoterol, used in the management of preterm labor was compared in the setting of a low-middle-income transitional country, Serbia & Montenegro. METHODS: This case study was conducted at the Gynecology-Obstetrics Clinic, Clinical Center "Kragujevac," in Kragujevac, Serbia & Montenegro, between October 2004 and January 2006. In total, 235 pregnant patients with threatened preterm labor were enrolled, but 35 were lost to follow-up. Of the remaining 200 patients, 85 were given ritodrine, and 115 fenoterol. The perspective of Republic Institute for Health Insurance in Serbia was taken into account. Only direct costs were calculated; primary outcomes of the study were length of pregnancy (in weeks), time passed from the onset of uterine contractions to delivery (in weeks), and score on modified Flanagan's quality-of-life scale for chronic diseases, measured after discharge from hospital. RESULTS: Prolongation of pregnancy was significantly longer in the fenoterol group (12.7 +/- 8.4 weeks) than in the ritodrine group (11.6 +/- 7.1 weeks). The mean duration of hospitalization was shorter in the fenoterol group (11.9 +/- 8.8 days) than in the ritodrine group (14.9 +/- 11.3 days). The treatment with fenoterol was less costly and more cost-effective than the treatment with ritodrine, but the difference in cost-effectiveness was not statistically significant. The cost of treatment per gained week of pregnancy prolongation was 3345.51 +/- 7668.04 CSD in the fenoterol group, and 4181.96 +/- 12,069.83 CSD in the ritodrine group. CONCLUSIONS: The observed differences in treatment costs and duration of hospitalization per patient did not translate into significant differences in cost-effectiveness ratios, because of low costs of hospitalization and human labor in Serbian health system. Nevertheless, fenoterol treatment still has a tendency to be more cost-effective, and its lower acquisition cost is an advantage to this treatment option.
Asunto(s)
Fenoterol/economía , Trabajo de Parto Prematuro/tratamiento farmacológico , Trabajo de Parto Prematuro/economía , Ritodrina/economía , Tocolíticos/economía , Adulto , Estudios de Cohortes , Análisis Costo-Beneficio/economía , Femenino , Fenoterol/uso terapéutico , Hospitales Universitarios/estadística & datos numéricos , Humanos , Montenegro , Programas Nacionales de Salud , Embarazo , Ritodrina/uso terapéutico , Clase Social , Tocolíticos/uso terapéutico , Resultado del Tratamiento , YugoslaviaRESUMEN
OBJECTIVE: The purpose of this study was to determine the optimal tocolytic agent, based on a cost decision analysis. STUDY DESIGN: A PubMed search of commonly used tocolytics was performed to determine the probability of adverse events. Cost for an agent was determined by acquisition cost and the probability and cost of adverse events. A decision tree was constructed to determine which tocolytic had the lowest total costs, with subsequent sensitivity analysis. RESULTS: A total of 19 clinical trials combined for a cohort of 1073 patients (indomethacin, 176 patients; magnesium sulfate, 451 patients; nifedipine, 176 patients; and terbutaline, 270 patients). The probability of adverse events was 57.9% for terbutaline, 22.0% for magnesium sulfate, 27.2% for nifedipine, and 11.4% for indomethacin. Nifedipine ($16.75) and indomethacin ($15.40) were the least expensive treatment options, compared with magnesium sulfate ($197.90) and terbutaline ($399.02) because of the cost of monitoring and treating adverse events. CONCLUSION: If one elects a tocolytic, both nifedipine and indomethacin should be the agents of choice, based on a cost decision analysis.
Asunto(s)
Trabajo de Parto Prematuro/tratamiento farmacológico , Tocolíticos/economía , Tocolíticos/uso terapéutico , Árboles de Decisión , Costos de los Medicamentos , Femenino , Humanos , Indometacina/efectos adversos , Indometacina/economía , Indometacina/uso terapéutico , Sulfato de Magnesio/efectos adversos , Sulfato de Magnesio/economía , Sulfato de Magnesio/uso terapéutico , Nifedipino/efectos adversos , Nifedipino/economía , Nifedipino/uso terapéutico , Trabajo de Parto Prematuro/prevención & control , Embarazo , Terbutalina/efectos adversos , Terbutalina/economía , Terbutalina/uso terapéutico , Tocolíticos/efectos adversosAsunto(s)
Anticonvulsivantes/uso terapéutico , Sulfato de Magnesio/uso terapéutico , Preeclampsia/tratamiento farmacológico , Tocolíticos/uso terapéutico , Anticonvulsivantes/efectos adversos , Anticonvulsivantes/economía , Circulación Cerebrovascular , Femenino , Humanos , Sulfato de Magnesio/efectos adversos , Sulfato de Magnesio/economía , Embarazo , Sudáfrica , Tocolíticos/efectos adversos , Tocolíticos/economíaAsunto(s)
Tocolíticos/uso terapéutico , Vasotocina/análogos & derivados , Vasotocina/uso terapéutico , Adulto , Ensayos Clínicos como Asunto/economía , Aprobación de Drogas , Costos de los Medicamentos , Diseño de Fármacos , Industria Farmacéutica , Europa (Continente) , Femenino , Humanos , Embarazo , Tocolíticos/economía , Estados UnidosRESUMEN
OBJECTIVE: To evaluate the cost of treating premature delivery with atosiban or beta-sympatomimetic drugs (fenoterol and hexoprenalin) from the perspective of health care payer--the medical insurance company. DESIGN: A pharmaco-economic model based on the results of randomized, controlled clinical study. SETTING: Hospital Pharmacy at Vitkovice Hospital of Blessed Mary Antonia, Ostrava. METHODS: The study is based on the application of clinical decision-making analysis, which includes results of a randomized controlled clinical study as well as data on the cost of clinical interventions and cost of drug therapy. The pharmaco-economic model was created from the perspective of the payer of health care--the insurance company. This model presumes the administration of atosiban or beta-sympatomimetic drugs (fenoterol and hexoprenalin) for the period of 18 and 48 h and the therapy of possible untoward effects for the next 72 h after the administration of the drugs. The analysis of sensitivity of pharmacokinetic model also employs so called low and high estimate of supplementary cost for the treatment of untoward effects. RESULTS: After the administration of the drugs for the period of 18 h the total cost of the payer of medical care was in the range of 21,914.5-21,974.4 CKr in atosiban, 19,878.7-22,661.4 CKr in fenoterol and 19,942.9-21,974.4 CKr in hexoprenalin. In the administration of the drugs for 48 h, the overall cost of the payer of medical care was in the range of 43,082.5-43,142.4 CKr in atosiban, 19,960.3-23,150.7 CKr in fenoterol and 20,131.3-23,574.0 in hexoprenalin. CONCLUSIONS: This study compared overall cost associated with hospitalization of a premature delivery from the perspective of the medical care payer, i.e. the health insurance company. The authors applied a pharmaco-economic model evaluating hospitalization for the period of 48 h and subsequent therapy of possible untoward effects for the period of up to 72 h. In case of a shorter administration of atosiban (up to 18 h) the overall cost of hospitalization for premature delivery for the period of 48 h from the point of view of medical insurance company is basically comparable with the administration of beta-sympatomimetic drugs. If atosiban is administered for more than 18 h, the overall cost of hospitalization is higher than with beta-sympatomimetic drugs, and the cost increases in relation to the duration of atosiban administration.
Asunto(s)
Fenoterol/economía , Hexoprenalina/economía , Reembolso de Seguro de Salud/economía , Trabajo de Parto Prematuro/tratamiento farmacológico , Trabajo de Parto Prematuro/economía , Tocolíticos/economía , Vasotocina/análogos & derivados , Vasotocina/economía , República Checa , Costos de los Medicamentos , Femenino , Fenoterol/efectos adversos , Fenoterol/uso terapéutico , Costos de la Atención en Salud , Hexoprenalina/efectos adversos , Hexoprenalina/uso terapéutico , Humanos , Modelos Económicos , Embarazo , Ensayos Clínicos Controlados Aleatorios como Asunto , Tocolíticos/efectos adversos , Tocolíticos/uso terapéutico , Vasotocina/efectos adversos , Vasotocina/uso terapéuticoRESUMEN
OBJECTIVE: This study was undertaken to study the effectiveness of continuous subcutaneous terbutaline (SQT) in the home after recurrent preterm labor (RPTL). STUDY DESIGN: Women with RPTL at less than 32 weeks' gestation were treated with continuous SQT administered in the home compared with matched control patients. RESULTS: Fifteen SQT patients were compared with 45 women (3:1) treated with no tocolytic therapy after hospitalization. Gestational age at delivery more than 37 weeks (53% vs 4%), percentage delivered at less than 32 weeks (0% vs 47%), overall and pregnancy prolongation (49.8 +/- 19.2 days vs 24.5 +/- 12.8 days) were all significantly better in the study group (P <.001). The total number of maternal hospital days (9.8 +/- 2.1 vs 15.9 +/- 7.4, P <.0001), duration of NICU stay (1.9 +/- 4.9 vs 19.8 +/- 29.3 days, P <.001), and total cost for newborn care (6,995 +/- 14,822 US dollars vs 62,033 +/- 89,978 US dollars, P <.002) favored the study patients. For every dollar spent on SQT, there was a savings of 4.67 US dollars in newborn hospital costs for control patients. CONCLUSION: In this small study, the use of SQT significantly prolongs pregnancy, decreases serious neonatal complications, and reduces the duration of hospitalization for both mother and infant, as well as neonatal costs.
Asunto(s)
Terapia de Infusión a Domicilio/economía , Cuidado Intensivo Neonatal/economía , Trabajo de Parto Prematuro/prevención & control , Terbutalina/administración & dosificación , Tocolíticos/administración & dosificación , Adulto , Australia , Estudios de Cohortes , Femenino , Costos de Hospital , Humanos , Recién Nacido , Bombas de Infusión , Inyecciones Subcutáneas , Tiempo de Internación , Trabajo de Parto Prematuro/economía , Embarazo , Recurrencia , Terbutalina/economía , Tocolíticos/economíaRESUMEN
OBJECTIVE: To compare the clinical and cost-effectiveness of treating recurrent preterm labor with continuous subcutaneous terbutaline versus oral tocolytics in twin gestations. STUDY DESIGN: In a retrospective, matched-cohort design, twin pregnancies treated as outpatients with continuous subcutaneous terbutaline were identified from a perinatal database, then matched 1:1 by gestational age at recurrent preterm labor to those receiving oral tocolytics. There were 353 patients per treatment group. A cost model was used to compare antepartum hospital, nursery, and outpatient charges. RESULTS: Infants of the subcutaneous terbutaline group had greater gestational age at delivery, higher birth weights, and less frequent neonatal intensive care unit admission. Charges for antepartum hospitalization and nursery were significantly less in the subcutaneous terbutaline group, while charges for outpatient services were less for the oral group. Mean total estimated charges were US$17,109 less for those receiving subcutaneous terbutaline. CONCLUSION: Improved clinical outcomes and decreased nursery utilization suggest cost-effectiveness of outpatient continuous subcutaneous terbutaline versus oral tocolytics for the treatment of recurrent preterm labor.